Literature DB >> 22581751

Prevalidation of a human cornea construct as an alternative to animal corneas for in vitro drug absorption studies.

Matthias Hahne1, Michaela Zorn-Kruppa, Gustavo Guzman, Johanna M Brandner, Eleonore Haltner-Ukomado, Hermann Wätzig, Stephan Reichl.   

Abstract

The use of ophthalmic drugs has increased consistently over the past few decades. Currently, most research is conducted using in vivo and ex vivo animal experiments; however, they have many disadvantages, including ethical concerns, high costs, the questionable extension of animal results to humans, and poor standardization. Although several cell culture-based cornea models have been developed, none have been validated and accepted for general use. In this study, a standardized, three-dimensional model of the human cornea (Hemicornea, HC) based on immortalized human corneal cells and cultivated in serum-free conditions was developed for drug absorption studies and prevalidated using compounds with a wide range of molecular characteristics (sodium fluorescein, rhodamine B, fluorescein isothiocyanate-labeled dextran, aciclovir, bimatoprost, dexamethasone, and timolol maleate). The HC model was independently cultured in three different laboratories, and the intralaboratory and interlaboratory reproducibility was analyzed and compared with the rabbit cornea. This analysis showed that the HC has a barrier in the same range as excised animal corneas, although with a higher reproducibility and lower variability. Because of the demonstrated transferability, the HC represents a promising in vitro alternative to the use of ex vivo tissue and offers a well-defined and standardized system for drug absorption studies.
Copyright © 2012 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22581751     DOI: 10.1002/jps.23190

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  8 in total

1.  Application of Mechanistic Ocular Absorption Modeling and Simulation to Understand the Impact of Formulation Properties on Ophthalmic Bioavailability in Rabbits: a Case Study Using Dexamethasone Suspension.

Authors:  Maxime Le Merdy; Jianghong Fan; Michael B Bolger; Viera Lukacova; Jessica Spires; Eleftheria Tsakalozou; Vikram Patel; Lin Xu; Sharron Stewart; Ashok Chockalingam; Suresh Narayanasamy; Rodney Rouse; Murali Matta; Andrew Babiskin; Darby Kozak; Stephanie Choi; Lei Zhang; Robert Lionberger; Liang Zhao
Journal:  AAPS J       Date:  2019-05-20       Impact factor: 4.009

2.  New Classes of Polycationic Compounds as Preservatives for Ophthalmic Formulations.

Authors:  Dörte von Deylen; Christina Dreher; Oliver Seidelmann; Stephan Reichl
Journal:  Pharm Res       Date:  2018-11-08       Impact factor: 4.200

3.  PLGA Nanoparticle Platform for Trans-Ocular Barrier to Enhance Drug Delivery: A Comparative Study Based on the Application of Oligosaccharides in the Outer Membrane of Carriers.

Authors:  Ge Jiang; Huanhuan Jia; Jindi Qiu; Junfeng Ban; Zhenjie Mo; Yifeng Wen; Yan Zhang; Yuqin Wen; Qingchun Xie; Zhufen Lu; Yanzhong Chen; Hao Wu; Qingchun Ni; Fohua Chen; Jiashu Lu; Zhijiong Wang; Haoting Li; Junming Chen
Journal:  Int J Nanomedicine       Date:  2020-11-24

4.  Establishment of a novel in vitro model of stratified epithelial wound healing with barrier function.

Authors:  Miguel Gonzalez-Andrades; Luis Alonso-Pastor; Jérôme Mauris; Andrea Cruzat; Claes H Dohlman; Pablo Argüeso
Journal:  Sci Rep       Date:  2016-01-13       Impact factor: 4.379

5.  Development of In Vitro Methodologies to Investigate Binding by Sodium Hyaluronate in Eye Drops to Corneal Surfaces.

Authors:  Udo Bock; Von Deylen D; Jochner M; Doerr M; Stäbler C; Reichl S
Journal:  Open Ophthalmol J       Date:  2018-07-31

6.  Microfluidic System for In Vivo-Like Drug Permeation Studies with Dynamic Dilution Profiles.

Authors:  Thomas Lorenz; Mona Kirschke; Verena Ledwig; Stephan Reichl; Andreas Dietzel
Journal:  Bioengineering (Basel)       Date:  2021-05-05

7.  Development of a curved, stratified, in vitro model to assess ocular biocompatibility.

Authors:  Cameron K Postnikoff; Robert Pintwala; Sara Williams; Ann M Wright; Denise Hileeto; Maud B Gorbet
Journal:  PLoS One       Date:  2014-05-16       Impact factor: 3.240

8.  Determining the Depth of Injury in Bioengineered Tissue Models of Cornea and Conjunctiva for the Prediction of All Three Ocular GHS Categories.

Authors:  Michaela Zorn-Kruppa; Pia Houdek; Ewa Wladykowski; Maria Engelke; Melinda Bartok; Karsten R Mewes; Ingrid Moll; Johanna M Brandner
Journal:  PLoS One       Date:  2014-12-10       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.